Abstract
ATM (ataxia-telangiectasia mutated) gene plays a central role in the DNA-damage response pathway. We characterized the ATM protein expression in immortalized cells from AT and AT-variant patients, and heterozygotes and correlated it with two ATM-dependent radiation responses, G1 checkpoint arrest and p53-Ser 15 phosphorylation. On Western blots, the full-length ATM protein was detected in eight of 18 AT cases, albeit at 1–32% of the normal levels, whereas a truncated ATM protein was detected in a single case, despite the prevalence among cases of truncation mutations. Of two ataxia without telangiectasia [A-(T)] cases, one expressed 20% and the other ~70% of the normal ATM levels. Noteworthy, among ten asymptomatic heterozygous carriers for AT, normal amounts of ATM protein were found in one and reduced by 40–50% in the remaining cases. The radiation-induced phosphorylation of p53 protein at serine 15, largely mediated by ATM kinase, was defective in AT, A(-T) and in 2/4 heterozygous carriers, while the G1 cell cycle checkpoint was disrupted in all AT and A(-T) cases, and in 3/10 AT heterozygotes. Altogether, our study shows that AT and A(-T) cases bearing truncation mutations of the ATM gene can produce modest amounts of full-length (and only rarely truncated) ATM protein. However, this limited expression of ATM protein provides no benefit regarding the ATM-dependent responses related to G1 arrest and p53-ser15 phosphorylation. Our study additionally shows that the majority of AT heterozygotes express almost halved levels of ATM protein, sufficient in most cases to normally regulate the ATM-dependent DNA damage-response pathway.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Athma P, Rappaport R and Swift M (1996) Molecular genotyping shows that ataxiatelangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92: 130–134
Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674–1677
Boder E (1985) Ataxia-telangiectasia: An overview. In: Ataxia-Telangiectasia: Genetics, Neuropathology and Immunology of a Degenerative Disease of Childhood, Gatti RA, Swift M (eds), pp. 1–63, Alan R. Liss: New York
Canman CE, Wolff AC, Chen CY, Fornace AJ and Kastan MB (1994) The p53 dependent G1 cell cycle checkpoint pathway and ataxia telangiectasia. Cancer Res 54: 5404–5458
Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sagakuchi K, Appella E, Kastan MB and Siliciano JD (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677–1679
Delia D, Greaves M, Villa S and DeBraud F (1984) Characterization of the response of human thymocytes and blood lymphocytes to the synergistic mitogenicity of 12-O-tetradecanoylphorbol-13-acetate (TPA)-ionomycin. Eur J Immunol 14: 720–724
Delia D, Goi K, Mizutani S, Yamada T, Aiello A, Fontanella E, Lamorte G, Iwata S, Ishioka C, Krajewski S, Reed JC and Pierotti MA (1997) Dissociation between cell cycle arrest and apoptosis can occur in Li–Fraumeni cells heterozygous for p53 gene mutations. Oncogene 14: 2137–2147
FitzGerald MG, Bean JM, Hedge SR, Unsal H, MacDonald DJ, Harkin DP, Finklestein DM, Isselbacher KJ and Haber DA (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15: 307–310
Gilad S, Khosravi R, Shkedy D, Uziel T, Ziv Y, Savitsky K, Rotman G, Smith S, Chessa L, Jorgenson TJ, Harnik R, Frydman M, Sanal O, Portnoi S, Goldwicz Z, Jaspers NGJ, Gatti RA, Lenoir G, Lavin MF, Tatsumi K, Wegner RD, Shiloh Y and Bar-Shira A (1996) Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 5: 433–439
Gilad S, Chessa L, Khosravi R, Russel P, Galanty Y, Piane M, Gatti RA, Jorgensen TJ, Shiloh Y and Bar-Shira A 1998 a) Genotype-phenotype relationships in Ataxia-Telangiectasia (A-T) and A-T variants. Am J Hum Genet 62: 551–561
Gilad S, Khosravi R, Harnik R, Ziv Y, Shkedy D, Galanty Y, Frydman M, Levi J, Sanal O, Chessa L, Smeets D, Shiloh Y and Bar-Shira A 1998 b) Identification of ATM mutations using extended RT-PCR and restriction endonuclease fingerprinting, and elucidation of the repertoire of A- Tmutations in Israel. Hum Mutat 11: 69–75
Hoekstra MF (1997) Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Curr Opin Genet Dev 7: 170–175
Janin N, Andrieu N, Ossian K, Laugé A, Croquette MF, Debré M, Bressac de Paillerets B, Aurias A and Stoppa-Lyonnet D (1999) Breast cancer risk in ataxia-telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 80: 1042–1045
Khanna KK, Beamish H, Yan J, Robson K, Williams R, Dunn I and Lavin MF (1995) Nature of G1/S cell cycle checkpoint in ataxia-telangiectasia. Oncogene 11: 609–618
Lakin ND, Weber P, Stankovic T, Rottinghaus ST, Taylor MAR and Jackson SP (1996) Analysis of the ATM protein in wild type and ataxia telangiectasia cells. Oncogene 13: 2707–2716
Lakin ND, Hann BC and Jackson SP (1999) The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 18: 3989–3995
Meyn SM (1995) Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res 55: 5991–6001
Morgan SE, Lovly C, Pandita TK, Shiloh Y and Kastan MB (1997) Fragments of ATM which have dominant negative or complementing activity. Mol Cell Biol 17: 2020–2029
Nakagawa K, Taya Y, Katsuyuki T and Yamaizumi M (1999) Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol 19: 2828–2834
Prudente S, Piane M, Brusco A, Saviozzi S, Carbonara A and Chessa L (1999) Mutations of the ATM gene in Italy recovered through different methodological approaches. Bull Cancer, in press
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277: 1497–1501
Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Tatanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor MAR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS and Shiloh Y 1995 a) A single ataxia telangiectasia gene with a product similar to Pl-3 kinase. Science 268: 1749–1753
Savitsky K, Sfez S, Tagle D, Ziv Y, Sartiel A, Collins FS, Shiloh Y and Rotman G 1995 b) The complete sequence of the coding region of the ATM gene reveales similarity to cell cycle regulators in different species. Hum Mol Genet 4: 2025–2032
Scott D, Hu Q and Roberts SA (1996) Dose-rate sparing for micronucleus induction in lymphocytes of controls and ataxia-telangiectasia heterozygotes exposed to 60Co γ- irradiation in vitro). Int J Radiat Biol 70: 521–527
Shieh SY, Ikeda M, Taya Y and Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325–334
Shigeta T, Takagi M, Delia D, Chessa L, Iwata S, Kanke Y, Asada M, Eguchi M and Mizutani S (1999) Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations. Cancer Res 59: 2602–2607
Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E and Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11: 3471–3481
Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P and Dohner H (1997) Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3: 1155–1159
Swift M, Morrel D, Cromartie E, Chamberlin R, Skolnick MH and Bishop DT (1986) The incidence and gene frequency of ataxia-telangiectasia in the United states. Am J Hum Genet 39: 573–583
Swift M, Morrell D, Massey RB and Chase CL (1991) Incidence of cancer in 161 families affected by Ataxia-Telangiectasia. New Engl J Med 325: 1831–1836
Takagi M, Delia D, Chessa L, Iwata S, Shigeta T, Kanke Y, Goi K, Asada M, Eguchi M, Kodama C and Mizutani S (1998) Defective control of apoptosis, radiosensitivity, and spindle checkpoint in ataxia-telangiectasia. Cancer Res 58: 4923–4929
Tchirkov A, Bay JO, Pernin D, Bignon YJ, Rio P, Grancho M, Kwiatkowski F, Giollant M, Malet P and Verrelle P (1997) Detection of heterozygous carriers of the ataxia-telangiectasia (ATM) gene by G2 phase chromosomal radiosensitivity of peripheral blood lymphocytes. Hum Genet 101: 312–316
Teraoka SN, Telatar M, Becker-Catania S, Liang T, Onengut S, Tolun A, Chessa L, Sanal O, Bernatowska E, Gatti RA and Concannon P Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. (1999). Am J Hum Genet 64: 1617–1631
Thacker J (1994) Cellular radiosensitivity in ataxia-telangiectasia. Int J Radiat Biol 66: S87–S96
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152–157
Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster ADB, Zaloudij J, Barbanti-Brodano G, James M, Russo G, Croce CM and Negrini M (1996) The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveal no evidence for mutations. Cancer Res 56: 2726–2732
Vorechovsky I, Luo L, Dyer MJS, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarstrom L, Websrter ADB and Yuille MAR (1997) Clustering of missense mutations in the ataxia telangiectasia gene in a sporadic T-cell leukemia. Nat Genet 17: 96–99
Walworth NC and Bernards R (1997) Rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint. Science 271: 353–356
Watters D, KK Khanna, Beamish H, Birrel G, Spring K, Kedar P, Gatei K, Stenzel D, Hobson K, Kozlov S, Zhang N, Farrel A, Ramsay J, Gatti R and Lavin M (1997) Cellular localization of the ataxia-telangiectasia (ATM)gene product and discrimination between mutated and normal form. Oncogene 14: 1911–1921
West CML, Elyan SAG, Berry P, Cowan R and Scott D (1995) A comparison of the radiosensitivty of lymphocytes from normal donors, cancer patients individuals with ataxia-telangiectasia (A-T) and AT heterozygotes. Int J Radiat. Biol 68: 197–203
Westphal CH, Schmaltz C, Rowan S, Elson A, Fisher DE and Leder P (1997) Genetic interaction between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res 57: 1664–1667
Wright J, Teraoka S, Onegut S, Tolun A, Gatti RA, Ochs HD and Concannon P (1996) A high frequency of distinct ATM mutations in ataxia-telangiectasia. Am J Hum Genet 59: 839–846
Zhang N, Chen P, KK Khanna, Scott S, Gatei M, Kozlov S, Watters D, Spring K, Yen T and Lavin MF (1997) Isolation of full length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Proc Natl Acad Sci USA 94: 8021–8026
Ziv Y, Bar-Shir A, Pecker I, Russel P, Jorgesen TJ, Tsarfati I and Shiloh Y (1997) Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 15: 159–157
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Delia, D., Mizutani, S., Panigone, S. et al. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes. Br J Cancer 82, 1938–1945 (2000). https://doi.org/10.1054/bjoc.2000.1168
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1168
Keywords
This article is cited by
-
Bone Marrow Failure and Immunodeficiency Associated with Human RAD50 Variants
Journal of Clinical Immunology (2023)
-
Differential molecular response in mice and human thymocytes exposed to a combined-dose radiation regime
Scientific Reports (2022)
-
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
Nature Communications (2018)
-
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia
Leukemia (2017)
-
DNA-damage response, survival and differentiation in vitro of a human neural stem cell line in relation to ATM expression
Cell Death & Differentiation (2009)